INDIVIDUAL TEST 874
ANNA-3 Antibodies
Indication
Suspicion of paraneoplastic neoplastic syndrome
Sample material
Serum
- Minim. volume: 0,5 mL
CSF
- Minim. volume: 0,5 mL
Transport
- Within Sweden: room temperature
- International: cold
Method
Indirect immunofluorescence (IIF)
Reference interval
Serum: <1:20 negative
CSF: <1:2 negative
Result
Results are reported as negative or positive. A positive result is followed by a titer (serum).
Interpretation
ANNA-3 is strongly associated with small cell lung cancer (SCLC) but has also been reported in adenocarcinoma. ANNA-3 is associated with sensory-motor neuropathy with or without ataxia, cerebellar ataxia, and brainstem encephalitis.
The antibodies may be present along with other paraneoplastic markers such as anti-Ri/Nova1 and calcium channel antibodies (VGCC).
References
- Banks SA et al. Ther Adv Neurol Disord. 2021. Autoimmune encephalopathies presenting as dementia of subacute onset and rapid progression. PMID: 33796145
- Gilligan M et al. Clin Biochem. 2024. Autoimmune central nervous system disorders: Antibody testing and its clinical utility. PMID: 38462203
Last updated: 2025-12-05
Can't find what you're looking for? We are here to help
ENSKILD ANALYS 874
ANNA-3-antikroppar
Indikation
Misstanke om paraneoplastiskt syndrom
Provmaterial
Serum
- Minim. volym: 0,5 mL
Likvor
- Minim. volym: 0,5 mL
Transport
- Inom Sverige: rumstemperatur
- Internationellt: kylt
Metod
Indirekt immunofluorescens (IIF)
Referensintervall
Serum: <1:20 negativt
Likvor: <1:2 negativt
Resultat
Resultat anges som negativt eller positivt. Positivt resultat titreras (serum).
Tolkning
ANNA-3 är starkt associerade med småcellig lungcancer (SCLC), men har också rapporterats vid adenocarcinom. ANNA-3 är associerade med sensomotorisk neuropati med eller utan ataxi, cerebellär ataxi och hjärnstamsencefalit.
Antikropparna kan förekomma tillsammans med andra paraneoplastiska markörer såsom anti-Ri/Nova1 och kalciumkanalsantikroppar (VGCC).
Referenser
- Banks SA et al. Ther Adv Neurol Disord. 2021. Autoimmune encephalopathies presenting as dementia of subacute onset and rapid progression. PMID: 33796145
- Gilligan M et al. Clin Biochem. 2024. Autoimmune central nervous system disorders: Antibody testing and its clinical utility. PMID: 38462203
Senast uppdaterat: 2025-12-05